Načítá se...
SRPX2 boosts pancreatic cancer chemoresistance by activating PI3K/AKT axis
BACKGROUND AND AIM: This investigation was aimed at disclosing whether SRPX2 affected pancreatic cancer (PC) chemoresistance by regulating PI3K/Akt/mTOR signaling. METHODS: Totally 243 PC patients were recruited, and they were incorporated into partial remission (PR) group, stable disease (SD) group...
Uloženo v:
| Vydáno v: | Open Med (Wars) |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
De Gruyter
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7718643/ https://ncbi.nlm.nih.gov/pubmed/33336063 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1515/med-2020-0157 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|